Experience in the treatment of psoriasis patients using Apremilast, a selective signalling pathway inhibitor

Abstract

The article presents a brief description of Аpremilast — the target synthetic anti-inflammatory drug, which is representative of a new class of agents for the treatment of psoriasis and psoriatic arthritis. The efficiency and safety of the new drug in the treatment of patients with severe psoriasis are shown.

Keywords

• psoriasis
• systemic therapy
• efficacy
• apremilast